CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.
July 14th 2017
Diane Zipursky Quale, co-founder of the Bladder Cancer Advocacy Network, discusses the importance of patients discussing their treatment options with their physician before undergoing surgery.
June 26th 2017
For patients with cisplatin-ineligible advanced urothelial cancer, frontline treatment with Keytruda (pembrolizumab) showed long-lasting response, according to updated phase 2 results from the KEYNOTE-052 trial.
June 20th 2017
Imfinzi (durvalumab) may change the treatment paradigm for some patients with urothelial carcinoma.
June 15th 2017
When used as a neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC), split-dose of gemcitabine and cisplatin has a beneficial response and a high safety profile, according to a study presented at the 2017 American Urological Association Annual Meeting.
June 7th 2017
Combined modality treatment (CMT) could be considered a first course of treatment for patients with muscle-invasive bladder cancer, according to the authors of a recent study published in the International Journal of Radiation Oncology.
June 6th 2017
When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.
June 1st 2017
According to results from the phase 3 RANGE trial, the addition of Cyramza (ramucirumab) to docetaxel resulted in improved progression-free survival for patients with previously treated locally advanced or unresectable or metastatic urothelial carcinoma.
June 1st 2017
Actress Marilu Henner spoke with CURE about her husband's journey with cancer and the importance of having the difficult conversations.
May 26th 2017
Edward Messing, M.D., discusses his recent paper which explored a possible way to reduce recurrence in some patients with bladder cancer.
May 24th 2017
Though deemed "safer" than normal cigarettes, electronic cigarettes may still pose a risk for bladder cancer.
May 23rd 2017
Arjun V. Balar, M.D., discusses Keytruda's impact on the treatment of urothelial carcinoma.
May 18th 2017
Keytruda (pembrolizumab) was granted an approval by the Food and Drug Administration (FDA) to treat some patients with locally advanced or metastatic urothelial carcinoma.
May 17th 2017
Bladder cancer is the sixth most common cancer in the U.S.
May 9th 2017
The Food and Drug Administration has granted an accelerated approval to the PD-L1 inhibitor Bavencio (avelumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.
May 1st 2017
The Food and Drug Administration has granted accelerated approval for durvalumab for treatment of patients with bladder cancer.
April 18th 2017
The FDA has granted an accelerated approval to Tecentriq as a frontline treatment for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.
April 7th 2017
In an interview with CURE, Evan Y. Yu, M.D., discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space and the possibilities for the future treatment landscape.
March 17th 2017
In an interview with CURE, Arlene O. Siefker-Radtke, M.D., discusses immune treatment and the immune landscape for the treatment of patients with urothelial cancers.
March 9th 2017
Charles Drake, M.D., Ph.D.. is optimistic about immunotherapy as it continues to move toward the frontline setting in GU cancers.
February 28th 2017
The FDA granted avelumab a priority review to a biologics license application to treat some patients with metastatic urothelial carcinoma, according to the developers of the drug.
February 25th 2017
Cabometyx combinations showed activity in patients with GU cancers, according to a preliminary clinical study.
February 23rd 2017
Patients with metastatic bladder cancer who did not see a benefit on single-agent Opdivo did better when the drug was combined with Yervoy, a recent study showed.
February 21st 2017
Checkpoint inhibitors drastically changed the treatment landscape of urothelial carcinoma, and more changes are on the way.
February 6th 2017
The FDA granted Keytruda a priority review for the treatment of some patients with urothelial carcinoma.
February 3rd 2017
Opdivo was granted an accelerated approval for a subset of patients with urothelial carcinoma.
February 2nd 2017
After results from a phase 3 trial showed that Keytruda improved overall survival, it may become the next standard of care for patients with advanced urothelial carcinoma.
January 18th 2017
The FDA recently issued a warning that a type of medicine used to treat Type 2 diabetes may increase a person's risk for developing bladder cancer.
January 10th 2017
Tecentriq (atezolizumab) is being reviewed for the use in additional settings to treat bladder cancer.